The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.25
Bid: 24.00
Ask: 24.50
Change: -1.00 (-3.96%)
Spread: 0.50 (2.083%)
Open: 25.25
High: 25.25
Low: 24.25
Prev. Close: 25.25
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect

Thu, 18th May 2023 14:31

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Commences a phase 1a clinical trial for its SDC-1801 treatment. Says patient recruitment is in progress at clinical units in Victoria, Australia. SDC-1801 is a potential therapeutic for a number of autoimmune diseases. Says application trial follows approval by the Human Research Ethics Committee, while the application has also been acknowledged by Australia's Therapeutic Goods Administration. Says phase 1b clinical study expected to begin in psoriasis patients in 2024.

----------

Nuformix PLC - London-based pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing - Says study data indicates its NXP002 treatment alone delivers an anti-inflammatory effect, suppressing the release of inflammatory cytokines by over 90%. Adds that the treatment shows an addition anti-inflammatory effect when used with current standards of care. Says results suggest NXP002 increases efficacy of existing therapies with the benefit of inhaled delivery. Says anti-inflammatory takes only an hour to have an effect, and strong effect lasts for 12 hours, and anti-inflammatory effect is still present after 24 hours. "I'm absolutely delighted with the data we've generated over recent months - all the results we've achieved are as good as we could have hoped for and are the first results from advanced 'close to patient' IPF and inflammation human tissue disease models," comments Executive director Dan Gooding.

----------

Conygar Investment Co PLC - London-based property investor and developer - Says Nottingham City Council has approved its application for the next phase of The Island Quarter development. Says application includes 23,123 square metre bioscience building, including laboratory and office space. Chief Executive Robert Ware comments: "We are delighted that the next phase of development has been approved. Nottingham is already home to a large number of exciting businesses in the bioscience space and this scheme will be an excellent addition to the mixed-use development we are creating at The Island Quarter".

----------

Secure Trust Bank PLC - Solihull, England-based savings accounts and lending services provider - Says net lending in the first quarter of 2023 was GBP3.01 billion, up 17% from GBP2.57 billion a year ago. New business lending rose 7.2% to GBP523.5 million, from GBP488.2 million, which it says demonstrates sustained growth momentum, in spite of tightened lending criteria. Adds that its cost optimisation programme is on track to deliver GBP4 million in annualised savings by the end of 2023. "We see significant opportunity for sustainable growth in our focused market segments and are well positioned to help consumers and businesses fulfil their ambitions and to continue to grow our net lending and scale our business as we strengthen our distribution networks and relationships...Although the economic environment remains uncertain, we have started the year positively and are confident in delivering on our plans for the full year and our medium term targets," Chief Executive David McCreadie says.

----------

Artemis Resources Ltd - Perth-based based mining company, with gold, copper and cobalt projects in Australia - Says historical geology and a data review confirms that its 2020 drill programme intercepted gold mineralisation within a quartz diorite intrusion. Says drilling has defined the intrusion over 2 kilometres, with elevated gold in rock chips over a strike length of 4 kilometres. Says there may be a possible relationship with Sanukitoid granitoids identified by De Grey Mining in the Mallina basin. Adds that an induced polarisation survey will begin in May, in order to help identify sulphides at depth. Exploration Manager Luke Meter says: "We have a new understanding of the importance of intrusion related gold in the Pilbara, including the identification of Sanukitoid like intrusions by the GSWA in the vicinity of the Karratha Granodiorite, some 2.5 km from Lulu Creek. The significance of the historic gold mineralisation therefore becomes apparent. With the Lulu Creek reconnaissance drill holes displaying similar grade and scale to De Grey's Diucon deposits, the potential upside for Lulu Creek is appreciable."

----------

By Harvey Dorset, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
19 Apr 2024 12:16

IN BRIEF: Sareum falls as issues shares to RiverFort Global

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company - Issues 3.0 million new shares in the company to RiverFort Global Opportunities PCC Ltd. Issue is in line with facility announced in August. Says facility has an outstanding balance of GBP220,000.

Read more
4 Apr 2024 17:24

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
2 Apr 2024 17:35

TRADING UPDATES: Sareum ups retail offer; SThree nabs former ITV exec

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
28 Mar 2024 13:44

EARNINGS AND TRADING: Northamber loss widens; Ethernity contract boost

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
15 Mar 2024 13:11

Sareum allowed European patent for primary kinase inhibitor asset

(Sharecast News) - Biotechnology company Sareum announced on Friday that the European Patent Office had issued a notice of allowance for a patent concerning SDC‐1801, its primary TYK2/JAK1 kinase inhibitor currently undergoing clinical trials in Australia.

Read more
15 Mar 2024 12:46

Sareum Holdings touts new patent allowance for autoimmune therapy

(Alliance News) - Sareum Holdings PLC on Friday celebrated a new patent allowance for SDC-1801, which is a therapy designed to treat a range of autoimmune diseases.

Read more
12 Mar 2024 15:23

Sareum shares slump on widened loss and funding talks

(Alliance News) - Sareum Holdings PLC share fell on Tuesday, after it said it expects to report a widened interim loss.

Read more
15 Feb 2024 13:22

Sareum reports positive progress in psoriasis programme

(Sharecast News) - Sareum announced significant milestones in its phase 1a clinical trial for SDC-1801, its lead programme aimed at addressing autoimmune diseases such as psoriasis, on Thursday.

Read more
15 Feb 2024 11:20

Sareum hails safety profile for SDC-1801 after phase 1 trial

(Alliance News) - Sareum Holdings PLC on Thursday said SDC-1801 has the potential to achieve therapeutically effective dose levels with no serious adverse events, following a phase 1 trial.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
2 Jan 2024 13:54

Sareum shares jump on cancer drug licensing deal

(Sharecast News) - Shares in AIM-listed biotech group Sareum jumped by a fifth on Tuesday after its co-development partner for cancer treatment SRA737 signed a commercialisation licence agreement with a US biopharma company.

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 10:05

AIM WINNERS & LOSERS: LungLife AI soars on test; Plexus falls on deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
2 Jan 2024 09:31

Sareum soars as partner agrees SRA737 licence with US biopharma firm

(Alliance News) - Sareum Holdings PLC shares surged on Tuesday, after it said its co-development partner CRT Pioneer Fund entered into a development and commercialisation licence for SRA737 with an unnamed US biopharmaceutical company.

Read more
14 Dec 2023 20:20

EARNINGS AND TRADING: CleanTech raises GBP520,000 in open offer

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.